AFT Pharmaceuticals Limited (AFT.NZ)

NZD 2.8

(0.0%)

EBITDA Summary of AFT Pharmaceuticals Limited

AFT Pharmaceuticals Limited's latest annual EBITDA in 2024 was 25.72 Million NZD , up 35.9% from previous year.
AFT Pharmaceuticals Limited's latest quarterly EBITDA in 2024 FY was N/A , up 26.1% from previous quarter.
AFT Pharmaceuticals Limited reported an annual EBITDA of 20.39 Million NZD in 2023, down -3.43% from previous year.
AFT Pharmaceuticals Limited reported an annual EBITDA of 21.12 Million NZD in 2022, up 69.88% from previous year.
AFT Pharmaceuticals Limited reported a quarterly EBITDA of 4.01 Million NZD for 2024 Q2, up 147.99% from previous quarter.
AFT Pharmaceuticals Limited reported a quarterly EBITDA of 11.25 Million NZD for 2024 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of AFT Pharmaceuticals Limited (2024 - 2013)

Historical Annual EBITDA of AFT Pharmaceuticals Limited (2024 - 2013)

Year	EBITDA	EBITDA Growth
2024	25.72 Million NZD	35.9%
2023	20.39 Million NZD	-3.43%
2022	21.12 Million NZD	69.88%
2021	12.43 Million NZD	-42.74%
2020	21.03 Million NZD	235.19%
2019	3.95 Million NZD	166.95%
2018	-9.67 Million NZD	31.52%
2017	-14.42 Million NZD	-38.88%
2016	-9.31 Million NZD	-76.49%
2015	-5.76 Million NZD	-268.85%
2014	3.41 Million NZD	13.8%
2013	2.99 Million NZD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	1.86 Million NZD	-88.23%
2024 Q2	4.01 Million NZD	147.99%
2024 Q4	11.25 Million NZD	0.0%
2024 Q3	11.25 Million NZD	143.13%
2024 FY	- NZD	26.1%
2023 Q3	8.63 Million NZD	92.82%
2023 Q2	4.47 Million NZD	116.65%
2023 FY	- NZD	-3.43%
2023 Q4	16.91 Million NZD	96.01%
2023 Q1	2.06 Million NZD	-86.48%
2022 Q1	2.85 Million NZD	-66.17%
2022 FY	- NZD	69.88%
2022 Q4	15.28 Million NZD	104.3%
2022 Q3	7.48 Million NZD	26.31%
2022 Q2	5.92 Million NZD	107.64%
2021 Q2	2.75 Million NZD	111.03%
2021 Q3	4.17 Million NZD	51.65%
2021 Q4	8.43 Million NZD	101.8%
2021 FY	- NZD	-42.74%
2021 Q1	1.3 Million NZD	-83.45%
2020 Q1	1.4 Million NZD	-56.75%
2020 Q2	4.17 Million NZD	196.98%
2020 Q4	7.89 Million NZD	66.48%
2020 Q3	4.73 Million NZD	13.46%
2020 FY	- NZD	235.19%
2019 Q1	188 Thousand NZD	114.94%
2019 FY	- NZD	166.95%
2019 Q4	3.25 Million NZD	0.0%
2019 Q3	3.25 Million NZD	1629.79%
2019 Q2	188 Thousand NZD	0.0%
2018 FY	- NZD	31.52%
2018 Q2	-2.94 Million NZD	0.0%
2018 Q3	-1.25 Million NZD	57.24%
2018 Q4	-1.25 Million NZD	0.0%
2018 Q1	-2.94 Million NZD	11.11%
2017 Q1	-4.03 Million NZD	63.39%
2017 Q3	-3.31 Million NZD	17.93%
2017 FY	- NZD	-38.88%
2017 Q4	-3.31 Million NZD	0.0%
2017 Q2	-4.03 Million NZD	0.0%
2016 Q2	-1.7 Million NZD	0.0%
2016 FY	- NZD	-76.49%
2016 Q4	-11.02 Million NZD	-340.09%
2016 Q3	-2.5 Million NZD	-47.24%
2016 Q1	-1.7 Million NZD	-129.86%
2015 Q4	-740 Thousand NZD	0.0%
2015 Q2	-2.14 Million NZD	0.0%
2015 FY	- NZD	-268.85%
2015 Q3	-740 Thousand NZD	65.44%
2015 Q1	-2.14 Million NZD	0.0%
2014 FY	- NZD	13.8%
2013 FY	- NZD	0.0%

Peer EBITDA Comparison of AFT Pharmaceuticals Limited

Name	EBITDA	EBITDA Difference
Greenfern Industries Limited	-1.45 Million NZD	1870.942%
Rua Bioscience Limited	-13.3 Million NZD	293.354%